Physician profile
Lawrence Broder
NPI 1467468736
$2,422.65
in general payments reported to CMS, 2019-2025
22 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $238 · 2021: $41.82 · 2024: $63.14 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $801.87 | 2019-2021 | |
| Galderma Laboratories, L.P. | $369.90 | 2019 | |
| Abbvie INC. | $335.00 | 2025 | |
| Novo Nordisk INC | $170.33 | 2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $107.61 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $70.63 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $63.65 | 2025 | Aptima |
| Allergan, INC. | $57.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.07 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $49.95 | 2025 | Proclaim |
| Pfizer INC. | $44.36 | 2024-2025 | |
| Inspire Medical Systems, INC. | $42.47 | 2025 | Inspire |
| Lilly USA, LLC | $37.42 | 2024-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $32.91 | 2025 | Airsupra |
| Alk-Abello, INC | $29.65 | 2025 | Ragwitek, Grastek, Odactra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $27.64 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $26.98 | 2025 | Auvelity |
| Ars Pharmaceuticals Operations, INC. | $26.13 | 2025 | Neffy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.32 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.13 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $16.88 | 2025 | Arexvy, Shingrix |
| Spinal Simplicity, LLC | $13.82 | 2025 | Ha Minuteman G3-R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Broder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.